Invitae

In an effort to lift patient access barriers, the company is launching a model whereby consumers will be able to initiate test orders online.

In a preliminary financial report, the company said it is expecting revenues of more than $144 million and to have tested more than 300,000 samples.

The index fell more than 11 percent in December, underperforming the Dow and the Nasdaq, but performing on par with the Nasdaq Biotechnology Index.

The investment bank called Genomic Health a leader in diagnostic testing and said Invitae will benefit from growth trends in the genetic testing sector.

The company accessioned approximately 78,000 samples in Q3 2018, up 95 percent from the year-ago quarter when it accessioned 40,000 samples..

Through the Alnylam Act program, patients suspected of having the rare disease or with a family history of the illness will receive testing at no cost.

The company plans to use the technology, originally developed by Good Start Genetics, to offer sample preparation solutions and data analysis for NGS.